Medpace Holdings Inc (MEDP) Major Shareholder Medpace Limited Partnership Sells 4,600,000 Shares
Medpace Holdings Inc (NASDAQ:MEDP) major shareholder Medpace Limited Partnership sold 4,600,000 shares of the firm’s stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total value of $138,736,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Medpace Holdings Inc (NASDAQ:MEDP) traded up $0.46 during midday trading on Thursday, reaching $33.66. 230,800 shares of the company’s stock were exchanged, compared to its average volume of 187,435. Medpace Holdings Inc has a 1 year low of $21.76 and a 1 year high of $39.64. The company has a market capitalization of $1,280.00 and a PE ratio of 22.58. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.36.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 earnings per share. research analysts anticipate that Medpace Holdings Inc will post 1.5 earnings per share for the current year.
MEDP has been the subject of several research analyst reports. Zacks Investment Research upgraded Medpace from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Saturday, September 9th. Robert W. Baird boosted their price objective on Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Medpace in a report on Tuesday, October 17th. Jefferies Group upped their target price on Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday, November 1st. Finally, William Blair downgraded Medpace from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $36.60.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.